Researchers test new drug for patients with neuroendocrine tumors
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma ...
Aug 6, 2012
0
0